BioSig to Present at Heart Rhythm 2022
Company’s conference program to include physician presentations and technology demonstrations, including features of its newly released PURE EP(TM) Nova-5 Software
Press Release
Company’s conference program to include physician presentations and technology demonstrations, including features of its newly released PURE EP(TM) Nova-5 Software
Press Release
In this feature interview, EP Lab Digest speaks with Dr. Gallinghouse to discuss his use of and thoughts on the PURE EP™ System, including workflow integration, improved signal technology, and recent study results at Texas Cardiac Arrhythmia Institute
Press Release
The seasoned electrophysiology sales executive joins the Company to expand the commercial footprint of its signal processing technology for arrhythmia care. Mr. Fleming brings to the Company over 20 years in the healthcare industry, including 17 years at Abbott Laboratories and St. Jude Medical.
Press Release
BioSig announced that it entered into a feasibility study with The Technion Research & Development Foundation Ltd. Under the terms of the program, the ECG signals supplied by PURE EP™ will be analyzed in the context of developing AI-powered algorithms for atrial fibrillation ablation procedures.
Press Release
BioSig announced that it is installing a PURE EP™ System for an evaluation at the HCA Healthcare-operated Medical City Heart Hospital in Dallas, TX. This is the Company’s 17th installation and its fifth in Texas, the state with some of the most extensive clinical programs focused on arrhythmia care in the country.
Press Release
Bioelectronic medicine is a new, rapidly growing field of healthcare that explores how targeted electrical signals in the body can help to diagnose and treat a wide range of diseases, from diabetes to depression.
BioSig aims to play a vital role in the field of bioelectronic medicine, based on our unique enabling technology and core competency in signal processing. Our initial focus is on heart disease and the fast-growing electrophysiology device market.
By improving signal clarity, BioSig’s PURE EP™ System has the potential to deliver valuable advances in electrophysiology procedures. Clinical data acquired by the PURE EP™ System in a multi-center study at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Mayo Clinic Jacksonville, and Massachusetts General Hospital was recently published in the Journal of Cardiovascular Electrophysiology. Study results showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP™ signals over conventional sources. Learn more from our physician users.
How Does Pure EP™ Work?BioSig is a NASDAQ-traded company with a clear path to commercialization and growth, proven credentials for success, and a world-class leadership team. Check out our Investor Resources for financial and governance information, stock performance, SEC filings, and other materials.